Clinical Outcomes in Rheumatoid Arthritis due to Tocilizumab Stock-out during COVID-19 Epidemics: A Short Case Series Report

Inês Barbosa¹, Ezequiel Pinto^{2, 3,} , Maria Graça Sequeira Munoz⁴, Tânia Nascimento^{2, 3} and Sandra Pais^{2, 5}

¹Faculty of Medicine and Biomedical Sciences, University of Algarve, Faro, Portugal

²University of Algarve, School of Health, Faro, Portugal

³Algarve Biomedical Center Research Institute - ABCRI, Faro, Portugal

⁴Centro Hospitalar Universitário do Algarve, Faro, Portugal

⁵Algarve Biomedical Center Research Institute - ABCRI, Faro, Portugal;Comprehensive Health Research Centre - CHRC, Lisboa, Portugal

Cite this paper

Inês Barbosa, Ezequiel Pinto, Maria Graça Sequeira Munoz, Tânia Nascimento and Sandra Pais. Clinical Outcomes in Rheumatoid Arthritis due to Tocilizumab Stock-out during COVID-19 Epidemics: A Short Case Series Report. American Journal of Medical Case Reports. 2022; 10(10):271-273. doi: 10.12691/AJMCR-10-10-5

Abstract

This short case-series reports a 6-month follow up of 5 rheumatoid arthritis patients (2 males, 3 females) 60 years-old or above, with Tocilizumab treatment which was discontinued due to stock off in July 2021. Patients switched treatment to other DMARD (Upadacitinib, Baricitinib, or Certolizumab pegol). We report clinical data and the Disease Activity Score for Rheumatoid Arthritis. Upadacitinib, Baricitinib, and Certolizumab appear therapeutically equivalent to Tocilizumab in a 6-month follow-up.

Keywords

Tocilizumab, rheumatoid arthritis

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Nishimoto, N., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Azuma, J., “Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study”, Ann Rheum Dis, 68 (10). 1580-4. 2009.
[2]	Malgie, J., Schoones, J.W., Pijls, B.G., “Decreased Mortality in Coronavirus Disease 2019 Patients Treated With Tocilizumab: A Rapid Systematic Review and Meta-analysis of Observational Studies”, Clin Infect Dis, 72 (11). E742-9. Jun.2001.
[3]	England, B.R., Tiong, B.K., Bergman, M.J., Curtis, J.R., Kazi, S., Mikuls, T.R., et al. “2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures”, Arthritis Care and Research, 71 (12). 1540-55. Dec.2019.
[4]	van der Heijde, D.M.F.M., Van’t Hof, M.A., van Riel, P.L.C.M., Theunisse, L.A.M., Lubberts, E.W., van Leeuwen, M.A., et al., “Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score”, Ann Rheum Dis, 49 (11). 916-20. 1990.
[5]	Lee, Y.H., Song, G.G., “Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs”, Zeitschrift fur Rheumatologie, 80 (4). 379-92. May.2021.
[6]	Rubbert-Roth, A., Enejosa, J., Pangan, A.L., Haraoui, B., Rischmueller, M., Khan, N., et al., “Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis”, New England Journal of Medicine, 383 (16). 1511-21. Oct.2020.
[7]	Mariette, X., Förger, F., Abraham, B., Flynn, A.D., Moltó, A., Flipo, R.M., et al., “Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study”, Annals of the Rheumatic Diseases, 77 (2). 228-33. Feb.2018.
[8]	Clowse, M.E., Förger, F., Hwang, C., Thorp, J., Dolhain, R.J., van Tubergen, A., et al., “Minimal to no transfer of certolizumab pegol into breast milk: Results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study”, Annals of the Rheumatic Diseases. 76 (11). 1890-6. Nov.2017.